Literature DB >> 12213277

Reduction of excitatory transmission in the retino-collicular pathway via selective activation of mGlu8 receptors by DCPG.

C A Pothecary1, D E Jane, T E Salt.   

Abstract

We have previously shown that activation of Group III metabotropic glutamate (mGlu) receptors modulates synaptic transmission in the superior colliculus. We thus investigated the effect of the selective mGlu8 receptor agonist (S)-3,4-dicarboxyphenylglycine (DCPG) on excitatory synaptic transmission in the superficial superior colliculus (SC) using an in vitro slice preparation of the rat SC. Field EPSPs evoked by optic tract stimulation under conditions of GABA receptor blockade were reduced by DCPG by up to 67.8+/-5.46% (EC(50) 1.25+/-0.56 microM), and this effect could be antagonised by LY341495 at a concentration (300 nM) known to be effective at mGlu8 receptors but not at mGlu4 or mGlu7 receptors. The broad-spectrum (mGlu4/mGlu7/mGlu8) agonist L-2-amino-4- phosphonobutyric acid (L-AP4) produced similar reductions of synaptic transmission (maximal reduction 68.6+/-2.33%; EC(50) 5.7+/-2.61 microM). These data are consistent with previous results which show that mGlu8 receptor activation can reduce synaptic transmission in the spinal cord, and indicate that similar mechanisms operate in other brain areas. Furthermore, this indicates that the mGlu8 receptor may have a role in the modulation of visual transmission in the superior colliculus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213277     DOI: 10.1016/s0028-3908(02)00077-1

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.

Authors:  P J Austin; M J Betts; M Broadstock; M J O'Neill; S N Mitchell; S Duty
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Modulation of GABAergic inhibition in the rat superior colliculus by a presynaptic group II metabotropic glutamate receptor.

Authors:  S A Neale; T E Salt
Journal:  J Physiol       Date:  2006-09-14       Impact factor: 5.182

Review 3.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

4.  Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata.

Authors:  M Broadstock; P J Austin; M J Betts; S Duty
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

5.  Changes in NMDA receptor contribution to synaptic transmission in the brain in a rat model of glaucoma.

Authors:  A L Georgiou; L Guo; M F Cordeiro; T E Salt
Journal:  Neurobiol Dis       Date:  2010-05-06       Impact factor: 5.996

6.  Selective activation of mGluR8 receptors modulates retinal ganglion cell light responses.

Authors:  S Quraishi; B T Reed; R M Duvoisin; W R Taylor
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

7.  Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence.

Authors:  Andrew C H Chen; Yongqiang Tang; Madhavi Rangaswamy; Jen C Wang; Laura Almasy; Tatiana Foroud; Howard J Edenberg; Victor Hesselbrock; John Nurnberger; Samuel Kuperman; Sean J O'Connor; Marc A Schuckit; Lance O Bauer; Jay Tischfield; John P Rice; Laura Bierut; Alison Goate; Bernice Porjesz
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-04-05       Impact factor: 3.568

8.  Presynaptic group I metabotropic glutamate receptors modulate synaptic transmission in the rat superior colliculus via 4-AP sensitive K(+) channels.

Authors:  Anne-Marie White; Risto A Kylänpää; Louisa A Christie; Simon J McIntosh; Andrew J Irving; Bettina Platt
Journal:  Br J Pharmacol       Date:  2003-11-17       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.